#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Acute leukaemia Mantle cell lymphoma Guillain-Barre syndrome Mixed-type liposarcoma Gastric cancer Penile cancer Cholangiosarcoma Hyperchylomicronaemia Obesity Immunodeficiency Myelodysplastic syndrome Langerhans' cell histiocytosis Autoimmune demyelinating disease Uterine leiomyosarcoma Giant cell tumour of tendon sheath More trials…

    Learn about Rare Diseases

    Carcinoid syndrome – Life with Disease Brain stem glioma – Basic Information Progressive multifocal leukoencephalopathy – Life with Disease Wiskott-Aldrich syndrome – Life with Disease Idiopathic pulmonary fibrosis – Trials in Disease Glomerulonephritis rapidly progressive – Treatment Noonan syndrome Testicular leiomyosarcoma – Treatment Acute respiratory distress syndrome – Treatment Systemic sclerosis pulmonary – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Glucocorticoids D5-Ethyl-Beta-D-Glucuronide Thiamine Hydrochloride Vismodegib Memantine Hydrochloride Sodium Chloride Solution 0.9% Cd7-Cart01 Rbl005.3 Isaralgagene Civaparvovec Cefoxitin Sodium ALG-000184 Int-787 Tertomotide Radiprodil Binimetinib Vibostolimab Travoprost Alanine VHB937 Cilastatin Sodium More therapies…

    Learn about Your Condition

    Gastrectomy Mantle cell lymphoma stage III Peritoneal sarcoma Placenta praevia Affective disorder Low cardiac output syndrome Fibromyalgia Dementia Alzheimer's type Alpha-1 antitrypsin deficiency Tendon injury Aicardi-Goutieres syndrome KBG syndrome Prostate cancer Malignant melanoma stage II Medulloblastoma recurrent More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Plasma cell myeloma

  • Study on Early Treatment for Multiple Myeloma Relapse Using Carfilzomib, Bortezomib, Daratumumab, Lenalidomide, and Dexamethasone in Patients with MRD Negativity

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Betamethasone Sodium Phosphate
    • Bortezomib
    • Carfilzomib
    Lithuania Norway

  • Study on Isatuximab and CellProtect for Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Evencaleucel
    • Isatuximab
    Sweden

  • Study of GEN3014 and Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma and Other Blood Cancers

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Daratumumab
    Czechia Denmark Greece Hungary Poland Spain +1

  • Study on KRd Consolidation for Multiple Myeloma Patients with Positive PET-CT: Carfilzomib, Lenalidomide, and Dexamethasone Treatment

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Dexamethasone Acetate
    • Carfilzomib
    Denmark Norway

  • Comparison of intravenous versus subcutaneous isatuximab with lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma patients eligible for transplant

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Isatuximab
    • Betamethasone Sodium Phosphate
    • Bortezomib
    Austria Germany

  • Study of Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Isatuximab
    • Bortezomib
    • Dexamethasone
    France
Previous Page
1 … 15 16 17 18 19 … 27
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!